Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for hospital use.
-
Clinical Benefit
Substantial |
The actual benefit of these proprietary products is substantial. |
Clinical Added Value
no clinical added value |
The comparative data for nasal fentanyl versus oral transmucosal fentanyl did not demonstrate superiority of INSTANYL relative to the comparator sharing the same indication ; INSTANYL does not bring an improvement in actual benefit (IAB V) in comparison with therapid-acting opioids indicated in the management of breakthrough pain episodes in adult patients using opioids to treat chronic cancer-related pain. |
Documents
English version
Contact Us
Évaluation des médicaments